The global gene therapy market is currently being driven by various factors, including the rising investments in the R&D activities, technological advancements, and growing prevalence of target diseases. The recent approvals of few gene therapies have created a promising future for the market. Also, most of the regulatory authorities are focusing on the approval of safe and efficient gene therapies. The major market players are collaborating with the academic and research institutes, which is boosting the R&D in this field. Currently, among the gene therapy products in development, recombinant adeno-associated virus (AAV)- based vectors are the most widely used ones and they show the highest potential for delivery in gene therapy indications. While the majority (around 74%) of AAV-based therapeutic products are in the process of clinical development (early to mid-phase), several promising clinical outputs have helped in progressing the pipeline of possible AAV-based products.

1. INTRODUCTION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET INSIGHTS

5. MARKET SEGMENTATION

6. COMPETITIVE LANDSCAPE

7. MARKET OPPORTUNITIES AND FUTURE TRENDS